Abstract
AbstractVaccination is one of the most widely used strategies to protect horses against pathogens. However, available equine vaccines often have limitations, as they do not always provide effective, long-term protection and booster injections are often required. In addition, research efforts are needed to develop effective vaccines against emerging equine pathogens. In this review, we provide an inventory of approved adjuvants for equine vaccines worldwide, and discuss their composition and mode of action when available. A wide range of adjuvants are used in marketed vaccines for horses, the main families being aluminium salts, emulsions, polymers, saponins and ISCOMs. We also present veterinary adjuvants that are already used for vaccination in other species and are currently evaluated in horses to improve equine vaccination and to meet the expected level of protection against pathogens in the equine industry. Finally, we discuss new adjuvants such as liposomes, polylactic acid polymers, inulin, poly-ε-caprolactone nanoparticles and co-polymers that are in development. Our objective is to help professionals in the horse industry understand the composition of marketed equine vaccines in a context of mistrust towards vaccines. Besides, this review provides researchers with a list of adjuvants, either approved or at least evaluated in horses, that could be used either alone or in combination to develop new vaccines.
Funder
Fonds Eperon
Conseil Régional de Haute Normandie
European Structural and Investment Funds
Institut Français du Cheval et de l’Equitation
Publisher
Springer Science and Business Media LLC
Reference115 articles.
1. Protecting the eu equine industry (2020). The European Task force for Brexit and EU Animal Health Law, a collaboration of the Key European Sport Horse and Thoroughbred horse racing and breeding industries, and formed by The International Sport Horse Confederation (IHSC)-constituted jointly by the Fédération Equestre Internationale (FEI) and the International Federation of Horse racing Authorities (IFHA). https://inside.fei.org/system/files/PROTECTING%20THE%20EU%20EQUINE%20INDUSTRY.pdf
2. Pronost S, Pitel PH, Miszczak F, Legrand L, Marcillaud-Pitel C, Hamon M, Tapprest J, Balasuriya UBR, Freymuth F, Fortier G (2010) Description of the first recorded major occurrence of equine viral arteritis in France. Equine Vet J 42:713–720. https://doi.org/10.1111/j.2042-3306.2010.00109.x
3. Australia. Commission of Inquiry into the August 2007 Outbreak of Equine Influenza in Australia. & Callinan, Ian D. F. (2008). Equine influenza: the August 2007 outbreak in Australia. [Canberra]: Commonwealth of Australia, https://nla.gov.au/nla.obj-961843962/view?partId=nla.obj-962289245#page/n3/mode/1up
4. Fougerolle S, Fortier C, Legrand L, Jourdan M, Marcillaud-Pitel C, Pronost S, Paillot R (2019) Success and limitation of Equine Influenza vaccination: the first incursion in a decade of a Florida Clade 1 Equine Influenza Virus that Shakes Protection Despite High Vaccine Coverage. Vaccines 7:174. https://doi.org/10.3390/vaccines7040174
5. Oladunni FS, Oseni SO, Martinez-Sobrido L, Chambers TM (2021) Equine influenza virus and vaccines. Viruses 13:1657. https://doi.org/10.3390/v13081657